VWA5A anticorps
Aperçu rapide pour VWA5A anticorps (ABIN7236362)
Antigène
Voir toutes VWA5A AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Attributs du produit
- Polyclonal Antibody
-
Purification
- Affinity purification
-
Immunogène
- Recombinant protein of human VWA5A
-
Isotype
- IgG
-
-
-
-
Indications d'application
- IHC 1:100-1:300
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.9 mg/mL
-
Buffer
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))
-
Autre désignation
- VWA5A
-
Sujet
- VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80 % of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.
-
UniProt
- O00534
Antigène
-